缺血性脑卒中与CYP450代谢途径的研究进展

Advances in research on ischemic stroke and CYP450 metabolic pathway

缺血性脑卒中是危害人类健康的主要疾病之一。近年研究发现,多不饱和脂肪酸(PUFA)及其经细胞色素P450 (cytochrome P450,CYP)途径代谢的产物参与缺血性脑卒中的生理病理过程。血浆中ω-3多不饱和脂肪酸(ω-3 PUFA)、20-羟基二十碳四烯酸(20-HETE)和环氧二十碳三烯酸(EETs)浓度水平可反映疾病的预后,对CYP450途径代谢酶进行诱导或抑制可改善神经功能。此外,CYP2C19基因型与氯吡格雷抗血小板治疗效果及复发性缺血性脑卒中有关,因而鉴定基因型和选择合理治疗方案尤为重要。本文就缺血性脑卒中与CYP450代谢途径相关研究进展进行综述。

Ischemic stroke is one of the major diseases that endanger human health in the world. In recent years, studies have found that polyunsaturated fatty acids(PUFA) and its products metabolized by the cytochrome P450(CYP450) pathway are involved in the physiological and pathological processes of cerebral ischemic stroke. Not only the prognosis of the disease can be predicted by detecting the plasma concentration levels of ω-3 Polyunsaturated fatty acid(ω-3 PUFA), 20-hydroxyeicosatetraenoic acid(20-HETE), and epoxyeicosatrienoic acids(EETs), but also the CYP450 pathway metabolic enzyme can be induced or inhibited to change the concentration of related products, thereby improving the neurological function. In addition, the CYP2C19 genotype is associated with the effect of clopidogrel antiplatelet therapy and recurrent ischemic stroke, so it is important for identifying genotypes and selecting a reasonable treatment regimen. This article reviews the research progress of ischemic stroke and CYP450 metabolic pathway.